Effect of synbiotics on uremic toxins in hemodialysis patients
- Conditions
- Chronic Kidney Disease stage 5DChronic Kidney Disease
- Registration Number
- JPRN-jRCTs031230290
- Lead Sponsor
- Goda Tomohito
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
1) Maintenance hemodialysis patients who are outpatients at the time of informed consent
2) Patients who introduced hemodialysis more than 6 months after consent was obtained
3) Patients who can self-medicate
4) Patients who are 18 years of age or older, have the ability to consent, and are able to obtain written consent of their own free will.
1) Patients with dementia
2) Patients with inflammatory bowel disease, history of lower gastrointestinal surgery, marked ascites due to liver disease, active malignant tumor
3) Patients who cannot stop taking other probiotics and synbiotic preparations, including supplements, from 2 weeks before the start of study drug administration until the end of the study
4) Patients who cannot stop taking Lubiprostone, Linaclotide, and Elobixibat and general antiflatulent drugs from 2 weeks before the start of study drug administration until the end of the study
5) Patients taking many sleeping pills
6) Patients who are allergic to potatoes, corn, Lactobacillus/Bifidobacterium beverages/foods, and dairy products
7) Women who are pregnant, may become pregnant, or are breastfeeding
8) Patients with other conditions that the investigators judge to be inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method